Cargando…

Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update()

There is an emerging body of evidence regarding the use of immunotherapy in early-stage triple negative breast cancer (TNBC), with the recent publication of several phase III and randomised phase II studies examining the role of immune checkpoint inhibitors (ICI) in the neoadjuvant setting in combin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Lauren C., Loi, Sherene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097806/ https://www.ncbi.nlm.nih.gov/pubmed/34996667 http://dx.doi.org/10.1016/j.breast.2021.12.018

Ejemplares similares

Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
por: Dixon-Douglas, Julia, et al.
Publicado: (2023)

Triple-negative breast cancer: recent treatment advances
por: Bergin, Alice R T, et al.
Publicado: (2019)

Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
por: Loi, Sherene, et al.
Publicado: (2022)

Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment
por: Zhang, Jinguo, et al.
Publicado: (2023)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

Update on systemic treatment in early triple negative breast cancer
por: Núñez Abad, Martín, et al.
Publicado: (2021)

Immune checkpoints: A therapeutic target in triple negative breast cancer
por: Chawla, Akhil, et al.
Publicado: (2014)

Checkpoint blockade in the treatment of breast cancer: current status and future directions
por: Wein, Lironne, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
por: Qureshi, Sadaf, et al.
Publicado: (2022)

Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer
por: Teo, Zhi Ling, et al.
Publicado: (2023)

An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers
por: Bottai, Giulia, et al.
Publicado: (2016)

Targeting immune checkpoints in breast cancer: an update of early results
por: Solinas, Cinzia, et al.
Publicado: (2017)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Advances in the Management of Early-Stage Triple-Negative Breast Cancer
por: Bhardwaj, Prarthna V., et al.
Publicado: (2023)

Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection
por: Criscitiello, Carmen, et al.
Publicado: (2010)

Update Breast Cancer 2021 Part 4 – Prevention and Early Stages
por: Thomssen, Christoph, et al.
Publicado: (2022)

Update Breast Cancer 2021 Part 1 – Prevention and Early Stages
por: Stickeler, Elmar, et al.
Publicado: (2021)

Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer?
por: Klinke, David J
Publicado: (2014)

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
por: Camorani, Simona, et al.
Publicado: (2020)

PTPN2 elicits cell autonomous and non–cell autonomous effects on antitumor immunity in triple-negative breast cancer
por: Goh, Pei Kee, et al.
Publicado: (2022)

Screening potential immune signatures for early-stage basal-like/triple-negative breast cancer
por: Wu, Min, et al.
Publicado: (2022)

Is breast conservation superior to mastectomy in early stage triple negative breast cancer?
por: Saifi, Omran, et al.
Publicado: (2022)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
por: Heeke, Arielle L., et al.
Publicado: (2021)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

The Iron-Inflammation Axis in Early-Stage Triple-Negative Breast Cancer
por: Duan, Fangfang, et al.
Publicado: (2022)

Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer
por: Nederlof, Iris, et al.
Publicado: (2023)

ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
por: Punie, K., et al.
Publicado: (2020)

Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance
por: Kim, Hyungjoo, et al.
Publicado: (2022)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
por: Xin, Yuanfang, et al.
Publicado: (2021)

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer
por: Scarpa, Joseph R., et al.
Publicado: (2023)

Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression
por: Asano, Yuka, et al.
Publicado: (2018)

Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges
por: Uchimiak, Katarzyna, et al.
Publicado: (2022)

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020)

Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
por: Poddar, Arpita, et al.
Publicado: (2022)

Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies
por: Abuhadra, Nour, et al.
Publicado: (2022)

Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer
por: Ren, Xijiao, et al.
Publicado: (2023)

Immune-Activated Regional Lymph Nodes Predict Favorable Survival in Early-Stage Triple-Negative Breast Cancer
por: Chen, Yi-Yu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qj3mqj844i3eqa52h6mbb55t9n